No, Brio Ellipta and Trelegy Ellipta Should Not Be Given Together
These two inhalers should never be prescribed together as they contain overlapping medication classes that would result in dangerous duplication of therapy. Specifically, both contain a LABA (long-acting beta-agonist), which would lead to excessive beta-agonist exposure and increased risk of cardiovascular adverse effects including tachycardia, arrhythmias, and potentially cardiac arrest 1.
Understanding the Medication Components
Brio Ellipta contains:
- Indacaterol (LABA)
- Glycopyrrolate (LAMA - long-acting muscarinic antagonist)
This is a LAMA/LABA dual bronchodilator combination.
Trelegy Ellipta contains:
- Fluticasone furoate (ICS - inhaled corticosteroid)
- Umeclidinium (LAMA)
- Vilanterol (LABA)
This is a LAMA/LABA/ICS triple therapy combination.
Why This Combination Is Inappropriate
Using both inhalers simultaneously would result in:
Double LABA therapy (indacaterol + vilanterol): This creates excessive beta-agonist stimulation with serious cardiovascular risks including seizures, angina, hypertension, tachycardia up to 200 beats/min, arrhythmias, and potentially cardiac arrest and death 1
Double LAMA therapy (glycopyrrolate + umeclidinium): This provides no additional benefit and increases anticholinergic side effects
Redundant bronchodilation: The therapeutic mechanisms completely overlap
The Correct Treatment Algorithm
According to the 2023 Canadian Thoracic Society guidelines 2:
For patients at LOW risk of exacerbations:
- Start with LAMA/LABA dual therapy (like Brio Ellipta)
- If inadequate symptom control → step up to LAMA/LABA/ICS triple therapy (like Trelegy Ellipta)
- Replace, don't add - discontinue the dual therapy when initiating triple therapy
For patients at HIGH risk of exacerbations:
- Start directly with LAMA/LABA/ICS triple therapy (Trelegy Ellipta), which has demonstrated mortality reduction 2
Clinical Decision Points
When to use Brio Ellipta (LAMA/LABA):
- Low exacerbation risk (< 2 moderate or < 1 severe exacerbation/year)
- CAT ≥ 10 or mMRC ≥ 2
- FEV1 < 80% predicted
- Preferred over ICS/LABA due to lower pneumonia risk 2
When to switch to Trelegy Ellipta (LAMA/LABA/ICS):
- High exacerbation risk (≥ 2 moderate or ≥ 1 severe exacerbation/year)
- Persistent symptoms despite LAMA/LABA therapy
- Concomitant asthma features 2
- Mortality benefit demonstrated in high-risk patients 2
Common Prescribing Error to Avoid
The critical mistake is thinking "more inhalers = better control." In reality, stepping up means replacing, not adding. When transitioning from dual to triple therapy, the dual therapy inhaler must be discontinued. The triple therapy already contains all the bronchodilator components plus the added ICS.
Single-inhaler triple therapy like Trelegy Ellipta has demonstrated superior outcomes compared to using multiple separate inhalers 2, making it the preferred approach when triple therapy is indicated.